| Smoky Ridge Health & Rehabilitation | |
| 310 Pensacola Road, Burnsville, North Carolina 28714 | |
| (828) 682-9759 | |
| Name | Smoky Ridge Health & Rehabilitation |
|---|---|
| Location | 310 Pensacola Road, Burnsville, North Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 140 |
| Occupancy Rate | 48.5% |
| Medicare ID (CCN) | 345305 |
| Legal Business Name | Senior Care Group Of Yancey Llc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1053395210 |
| Organization Name | SENIOR CARE GROUP OF YANCEY LLC |
| Doing Business As | BROCKSIDE REHABILITATION AND CARE |
| Address | 310 Pensacola Rd, Burnsville, NC 28714 |
| Phone Number | 828-682-9759 |
News Archive
Why do so many people continue to suffer from life-altering, chronic pain long after their injuries have actually healed"
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.
Optegra Eye Health Care's flagship Central London hospital, situated in the prestigious Harley Street district, has given the gift of improved vision back to hundreds of people since first opening its doors in January 2016.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 9 days ago
| NPI Number | 1558029488 |
| Organization Name | SMOKEY RIDGE HEALTH AND REHABILITATION SNF LLC |
| Address | 310 Pensacola Rd, Burnsville, NC 28714 |
| Phone Number | 828-682-9759 |
News Archive
Why do so many people continue to suffer from life-altering, chronic pain long after their injuries have actually healed"
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.
Optegra Eye Health Care's flagship Central London hospital, situated in the prestigious Harley Street district, has given the gift of improved vision back to hundreds of people since first opening its doors in January 2016.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 9 days ago
| NPI Number | 1871676015 |
| Organization Name | SENIOR CARE GROUP LLC |
| Doing Business As | BROOKSIDE REHABILITATION & CARE |
| Address | 310 Pensacola Rd, Burnsville, NC 28714 |
| Phone Number | 828-682-9759 |
News Archive
Why do so many people continue to suffer from life-altering, chronic pain long after their injuries have actually healed"
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.
Optegra Eye Health Care's flagship Central London hospital, situated in the prestigious Harley Street district, has given the gift of improved vision back to hundreds of people since first opening its doors in January 2016.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Why do so many people continue to suffer from life-altering, chronic pain long after their injuries have actually healed"
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.
Optegra Eye Health Care's flagship Central London hospital, situated in the prestigious Harley Street district, has given the gift of improved vision back to hundreds of people since first opening its doors in January 2016.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $10198 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.9 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.04 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 47.17 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.2 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.37 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.63 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 7.86 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.45 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20.08 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 93.7 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 46.62 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 33.58 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.94 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 93.95 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 32.86 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 87.78 | 82.93 |
News Archive
Why do so many people continue to suffer from life-altering, chronic pain long after their injuries have actually healed"
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.
Optegra Eye Health Care's flagship Central London hospital, situated in the prestigious Harley Street district, has given the gift of improved vision back to hundreds of people since first opening its doors in January 2016.
ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.
› Verified 9 days ago
Smoky Ridge Health & Rehabilitation Location: 310 Pensacola Road, Burnsville, North Carolina 28714 Phone: (828) 682-9759 |